Clinical Trial

A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will evaluate the tolerability and acceptability of injection site reactions (ISRs) of two long-acting (LA) injectables. Additional characteristics of the ISRs will be investigated and described as well as safety outcomes.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-05; most recent amendment 2025-11-21.
Status change: Recruiting → Active, Not Recruiting 2025-07-16
Trial Details
NCT Number NCT06970223
Lead Sponsor ViiV Healthcare
Conditions HIV Infections
Enrollment 65 participants
Start Date 2025-04-22
Primary Completion 2025-07-15 (estimated)
Study Completion 2026-07-10 (estimated)
Updated on ClinicalTrials.gov 2025-11-28